Key result
Simulations of preemptive multigene pharmacogenomic testing projected 26.5 and 41.2 actionable prescribing opportunities per 100 patients in PCI and allo-HCT populations, respectively.
Why the study?
To evaluate the potential impact of preemptive multigene pharmacogenomic testing on medication prescribing in real-world clinical settings.
Does preemptive multigene pharmacogenomic testing identify actionable prescribing opportunities in PCI and allo-HCT patients?
Cohort (n=346)
No
Does preemptive multigene pharmacogenomic testing identify actionable prescribing opportunities in PCI and allo-HCT patients?
Preemptive multigene pharmacogenomic testing could identify 26.5 and 41.2 actionable prescribing interventions per 100 PCI and allo-HCT patients, respectively, beyond standard single-gene testing.
Aim: To evaluate the potential impact of preemptive multigene pharmacogenomic (PGx) testing on medication prescribing in real-world clinical settings. Patients & methods: Prescription frequencies for 65 medications with actionable PGx recommendations were collected in 215 percutaneous coronary intervention (PCI) and 131 allogeneic hematopoietic cell transplant (allo-HCT) patients. A simulation projected the number of PGx-guided prescribing opportunities. Results: In PCI and allo-HCT patients, respectively, 66.5 and 90.1% were prescribed at least one medication with actionable PGx prescribing recommendations. Simulations projected 26.5 and 41.2 total PGx-guided prescribing opportunities per 100 PCI and allo-HCT patients, respectively, if multigene PGx results were available. Conclusion: A multigene PGx testing strategy offers potential to optimize medication prescribing beyond clopidogrel and tacrolimus in PCI and allo-HCT patients.
No takes yet. Share an insight, caveat, or question.
Ratner et al. (2022) conducted a cohort in Percutaneous coronary intervention and allogeneic hematopoietic cell transplant (n=346). Preemptive multigene pharmacogenomic (PGx) testing was evaluated on Total number of projected clinically actionable PGx-guided medication interventions per 100 patients. Simulations of preemptive multigene pharmacogenomic testing projected 26.5 and 41.2 actionable prescribing opportunities per 100 patients in PCI and allo-HCT populations, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: